Endpoints News
Ocugen heads to Phase 3 with gene therapy for geographic atrophy
Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday from a smaller study.
The gene therapy is for patients …